Trial Profile
A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Bial
- 11 Sep 2012 Results presented at the 16th Congress of the European Federation of Neurological Societies.
- 31 Jan 2012 New trial record